Osamu Nakashima
- Hepatology top 0.1%
- Epidemiology top 0.5%
- Surgery top 1%
- Oncology top 1%
- Cancer Research top 1%
- Co-authors
- Masamichi KojiroMasatoshi KudoNamiki IzumiMichiie SakamotoNorihiro KokudoYutaka MatsuyamaOsamu MatsuiMasatoshi Makuuchi
- Topics
- Hepatocellular Carcinoma Treatment and Prognosis (85 papers)Liver Disease Diagnosis and Treatment (48 papers)Cholangiocarcinoma and Gallbladder Cancer Studies (41 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaPLoS ONE
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Osamu Nakashima
194 papers receiving 7.3k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Hepatology 4.6k
- Epidemiology 2.9k
- Surgery 2.2k
- Oncology 1.7k
- Cancer Research 1.2k
Countries citing papers authored by Osamu Nakashima
This map shows the geographic impact of Osamu Nakashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Osamu Nakashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Osamu Nakashima more than expected).
Fields of papers citing papers by Osamu Nakashima
This network shows the impact of papers produced by Osamu Nakashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Osamu Nakashima. The network helps show where Osamu Nakashima may publish in the future.
Co-authorship network of co-authors of Osamu Nakashima
This figure shows the co-authorship network connecting the top 25 collaborators of Osamu Nakashima. A scholar is included among the top collaborators of Osamu Nakashima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Osamu Nakashima. Osamu Nakashima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 27 | |
| 3 | 33 | |
| 4 | 74 | |
| 5 | 177 | |
| 6 | 30 | |
| 7 | Expression of HSP27 in Hepatocellular Carcinoma. | 20 |
| 8 | 48 | |
| 9 | 6 | |
| 10 | 2 | |
| 11 | 1 | |
| 12 | 4 | |
| 13 | 4 | |
| 14 | 2 | |
| 15 | 19 | |
| 16 | 1 | |
| 17 | 6 | |
| 18 | 10 | |
| 19 | 11 | |
| 20 | 2 |
About Osamu Nakashima
Osamu Nakashima is a scholar working on Hepatology, Cancer Research and Epidemiology, having authored 204 papers that have together received 7.5k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (85 papers), Liver Disease Diagnosis and Treatment (48 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (41 papers). The work is most often cited by research in Hepatology (4.6k citations), Epidemiology (2.9k citations) and Cancer Research (1.2k citations). Osamu Nakashima has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Masamichi Kojiro, Masatoshi Kudo, Namiki Izumi, Michiie Sakamoto, Norihiro Kokudo, Yutaka Matsuyama, Osamu Matsui, Masatoshi Makuuchi, M Kojiro and Yonson Ku. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.